Skip to content

The comparision of sertaconazole versus pimecrolimus in the treatment of facial seborrheic dermatitis

The comparision study of sertaconazole 2% cream versus pimecrolimus 1% cream in the treatment of facial seborrheic dermatitis

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2014041613853N1
Enrollment
60
Registered
2014-04-16
Start date
2014-04-01
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Seborrheic dermatitis (SD). Seborrhoeic dermatitis

Interventions

Intervention 1: Topical pimecrolimus cream 1% will be given to the 30 patients. They will be recommended to use tip finger amount of cream to each involved area, 2 times daily for 4 weeks. The Patient
Treatment - Drugs
Topical pimecrolimus cream 1% will be given to the 30 patients. They will be recommended to use tip finger amount of cream to each involved area, 2 times daily for 4 weeks. The Patients will be visite
Topical sertaconazole cream 2% will be given to the 30 patients. They will be recommended to use tip finger amount of cream to each involved area, 2 times daily for 4 weeks. The Patients will be visit

Sponsors

Vice-chancellor for research -Semnan University of Medical Science
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: inclusion criteria: facial seborrheic dermatitis; any systemic disease. exclusion criteria: taking drugs such as methyldopa, chlorpromazine, cimetidine; use of local and systemic anti-acne ,steroid and immune modulators drugs one month before; lactation and pregnancy.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Improvment. Timepoint: 2 and 4 weeksafter starting treatment. Method of measurement: dermatologist examination.;Exacerbation. Timepoint: 1 month after stoping treatment. Method of measurement: dermatologist examination.;Treatment duration. Timepoint: 4 weeks. Method of measurement: time.;Patient satisfaction. Timepoint: 2 and 4 weeks after starting treatment. Method of measurement: question of patient.

Secondary

MeasureTime frame
Side effect. Timepoint: 2 and 4 weeks after starting treatment. Method of measurement: dermatologist examination.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Azizzadeh

Semnan University of Medical Science

maryamazizzadeh@semums.ac.ir+98 23 1333 7856

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026